Afișare rezultate

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

Belperio John A.1, Nguyen Tuan2, Lombardi David A.2, Boguş Maxim34, Moskalenko Valentyn56, Singh Dave7, Haumann Brett8, Bourdet David L.2, Kaufman Elad2, Pfeifer Nathan D.2, Thompson Corbin G.2, Woo Jacky2, Moran Edmund J.2, Saggar Rajeev2

1 Ronald Reagan UCLA Medical Center, Los Angeles, 2 Theravance Biopharma Inc, South San Francisco, 4 Timofei Moșneaga Republican Clinical Hospital, 6 Brovary multidisciplinary clinical hospital, 8 Theravance Biopharma UK Limited, London

BMJ Open Respiratory Research

Nr. / 2023 / ISSN 2052-4439

Disponibil online 15 August, 2023. Descarcări-1. Vizualizări-144

-----------------------------------------------------------------------------------------------------------------------------------

A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19

Singh Dave123, Boguş Maxim4, Moskalenko Valentyn5, Noi Autori

3 Brovary multidisciplinary clinical hospital, 4 Timofei Moșneaga Republican Clinical Hospital,

European Respiratory Journal

Nr. / 2021 / ISSN 0903-1936 /ISSNe 1399-3003

Disponibil online 19 July, 2023. Descarcări-0. Vizualizări-188

-----------------------------------------------------------------------------------------------------------------------------------

10203040501005001000